AbbVie Inc's Fiscal Year is From January To December.
The item "Price-To-Tangible-Book-Ratio" stands at -6.63 as of 09/30/2025, the lowest value at least since 06/30/2022, the period currently displayed.
As of the end of AbbVie Inc's third quarter, the item "Price To Tangible Book Ratio" stands at -6.63. This represents a decrease of -21.70 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -1.26 compared to the value the year prior.
The Serie's long term average value is -5.21. It's latest available value, on 09/30/2025, is -1.43 lower, compared to it's long term average value.
The Serie's change from it's minimum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is +0.0 .
The Serie's change from it's maximum value, on 06/30/2022, to it's latest available value, on 09/30/2025, is -2.42 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price To Tangible Book Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Price To Tangible Book Ratio | 486,508,953,600.00 |
![]() | Roche Holding AG - Price To Tangible Book Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price To Tangible Book Ratio | 280,205,508,085.11 |
![]() | Novartis AG - Price To Tangible Book Ratio | 255,096,620,580.91 |